title: Evaluation of the effect of low-dose oral theophylline therapy on some bone turnover markers and serum prolidase I activity in mild asthmatics.
abstract: Hypercalcemia and hypercalciuria observed both in humans and in animals who were on long-term theophylline therapy, prompted us to investigate whether oral theophylline treatment at optimal doses causes any adverse side effects on bone metabolism in mild asthmatics. Therefore, serum osteocalcin (BGP) and total alkaline phosphatase (TALP, EC 3.1.3.1) as bone formation markers, serum prolidase I (EC 3.4.13.9) activity as a marker for collagen metabolism, urinary deoxypyridinoline (Dpd), hydroxyproline (Hyp) and fasting urinary calcium as bone resorption markers, were measured in 18 mild asthmatics who had been treated with theophylline over 1-10 years. Among measured bone turnover markers, BGP, TALP, and Hyp levels were found to be increased in mild asthmatics; and BGP showed the greatest percent mean increase (98%) over the healthy subjects. However, these increments did not exceed the upper reference limits. Serum prolidase I activity was also increased in mild asthmatics receiving theophylline. Our results indicate that theophylline therapy at optimal doses may not exert adverse side effects on bone homeostasis, but patients receiving supratherapeutic doses of theophylline should be under close examination in order to predict future bone mass status.
authors.affiliation: Department of Biochemistry, Istanbul Faculty of Medicine, Istanbul University, Capa, 34390, Turkey.
authors.forename: P
authors.initials: P
authors.lastname: Oner
authors.forename: F
authors.initials: F
authors.lastname: Gürdöl
authors.forename: Y
authors.initials: Y
authors.lastname: Oner-Iyidon
authors.forename: C
authors.initials: C
authors.lastname: Kolanci
authors.forename: S
authors.initials: S
authors.lastname: Büyüköztürk
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000187:drug effects / Q000378:metabolism; D000596:Amino Acids / Q000187:drug effects / Q000652:urine; D001249:Asthma / Q000188:drug therapy* / Q000473:pathology; D015415:Biomarkers / Q000032:analysis; D001862:Bone Resorption / Q000652:urine; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D002118:Calcium / Q000652:urine; D004150:Dipeptidases / Q000097:blood / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000187:drug effects / Q000652:urine; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood / Q000187:drug effects; D013806:Theophylline / Q000097:blood / Q000627:therapeutic use*; D013997:Time Factors; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D000596:Amino Acids; D015415:Biomarkers; D014665:Vasodilator Agents; D015675:Osteocalcin; C036020:deoxypyridinoline; D013806:Theophylline; D000469:Alkaline Phosphatase; D004150:Dipeptidases; C022449:proline dipeptidase; D006909:Hydroxyproline; D002118:Calcium